

Allergic Bronchopulmonary Aspergillosis

Paul A. Greenberger, MD^a, Robert K. Bush, MD^b, Jeffrey G. Demain, MD^c, Amber Luong, MD, PhD^d, Raymond G. Slavin, MD, MS^e, and Alan P. Knutsen, MD^f Chicago, Ill; Madison, Wis; Anchorage, Alaska; Houston, Tex; and St Louis, Mo

There remains a lack of agreement on diagnostic criteria and approaches to treatment of patients with allergic bronchopulmonary aspergillosis (ABPA). The results of a survey of American Academy of Allergy, Asthma, & Immunology members regarding these 2 issues are presented and compared for concordance with published recommendations. The literature was reviewed for pertinent reports, and an electronic survey was conducted of American Academy of Allergy, Asthma, & Immunology members and fellows regarding diagnostic criteria, numbers of patients evaluated for ABPA, and treatment approaches. From 508 respondents to the survey sent to 5155 US physicians in the American Academy of Allergy, Asthma, & Immunology database of members and fellows, 245 health professionals (48%) had treated at least 1 patient with ABPA in the previous year. For the diagnosis of ABPA, there was a difference in the threshold concentration of total serum IgE

because 44.9% used ≥ 417 kU/L, whereas 42.0% used ≥ 1000 kU/L. Analysis of these findings suggests that ABPA might be underdiagnosed. With regard to pharmacotherapy, oral steroids were recommended for 97.1% of patients and oral steroids plus inhaled corticosteroids plus antifungal agent were used with 41.2% of patients. The armamentarium for treatment of ABPA includes oral corticosteroids as the initial treatment with inhaled corticosteroids used for management of persistent asthma. Azoles remain adjunctive. Published experience with omalizumab has been limited. © 2014 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2014;2:703-8)

Key words: Allergic; Bronchopulmonar; Aspergillosis; Asthma; Mycosis; IgE; Azole

The global prevalence of allergic bronchopulmonary aspergillosis (ABPA) has been estimated to be as high as 2.5%,¹ yet, delays in diagnosis or undertreatment may lead to pulmonary fibrosis, bronchiectasis with chronic sputum production, and increasingly severe persistent asthma with loss of lung function. There are differences of opinion over the criteria for diagnosis, screening tests of patients with asthma, and how best to manage and treat the patient.² ABPA is almost always caused by *Aspergillus fumigatus*, which has intrinsic virulence, survival characteristics, proinflammatory actions, and enzymatic properties in susceptible hosts. The purpose of this review is to consider fungi implicated in allergic bronchopulmonary mycoses (ABPM), give a brief discussion of the immunopathology and approaches to management and treatment, and to report findings from a survey of allergist/immunologists in the American Academy of Allergy, Asthma, & Immunology (AAAAI) that explored the diagnostic criteria and treatments of ABPA.

ABPM

Since the original description of APBA in 1952,³ a number of other fungi or yeasts have been implicated as causing a similar clinical syndrome. Examples are listed in Table I. *A fumigatus* is by far responsible for the majority of these cases, but other fungi or yeasts have been identified when patients presented with features of ABPA (eg, pulmonary infiltrates with peripheral blood eosinophils, with or without bronchiectasis; underlying asthma) but lacked evidence of sensitization or recovery of *A fumigatus*. The culprit fungus was identified in sputum or airway samples, along with evidence of sensitization to the fungus by skin test or *in vitro* measurement. The diagnosis of ABPM, therefore, is predicated on the identification of fungi, other than *A fumigatus*, by appropriate culture or molecular biology techniques of patients with clinical features of ABPA. Often there is repeated recovery of the rare fungus or yeast that leads to the diagnosis. Because commercially available reagents for skin testing and for *in vitro* methods to detect

^aDivision of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill

^bDivision of Allergy-Immunology, Department of Medicine, University of Wisconsin, Madison, Wis

^cAllergy, Asthma and Immunology Center of Alaska, University of Washington, Anchorage, Alaska

^dOtolaryngology-Head and Neck Surgery, University of Texas Medical School at Houston, Houston, Texas

^eSection of Allergy-Immunology, Division of Infectious Diseases, Department of Internal Medicine, St Louis University, St Louis, Mo

^fDivision of Allergy-Immunology, Department of Pediatrics, St Louis University, St Louis, Mo

Supported by the Ernest S. Bazley Grant to Northwestern University and Northwestern Memorial Hospital (P. Greenberger); and by the National Institutes of Health Clinical and Translational Award UL1 TR000371, the National Center for Advancing Translational Research Award KL2 TR000370, and The Triological Society Research Career Development Award (A. Luong).

Conflicts of interest: P. A. Greenberger has received consultancy fees from Mylan for being on the Scientific Advisory Board; has provided expert testimony for several law firms not regarding allergic bronchopulmonary aspergillosis; received royalties from Wolters Kluwer Lippincott, Williams and Wilkins; and is a reviewer for UpToDate. R. K. Bush is an associate editor of *The Journal of Allergy and Clinical Immunology*; is section editor for *Current Allergy and Asthma Reports*; and is section editor of *Current Opinions in Allergy and Clinical Immunology*. A. Luong has received research support from the Triological Society, American Association of Otolaryngic Allergy, and the National Institutes of Health (NIH US4 AI082973). A. P. Knutsen has received research support from the National Institutes of Health for the Primary Immune Deficiency Treatment Consortium study, JMF Center, and Baxter for the SCGG study; has received lecture fees from CSL Behring; and receives royalties from UpToDate and eMedicine. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication May 23, 2014; revised August 20, 2014; accepted for publication August 21, 2014.

Corresponding author: Paul A. Greenberger, MD, Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago IL 60611. E-mail: p-greenberger@northwestern.edu.

2213-2198

© 2014 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaip.2014.08.007>

Abbreviations used

AAAAI-American Academy of Allergy, Asthma, & Immunology
 ABPA-Allergic bronchopulmonary aspergillosis
 ABPM-Allergic bronchopulmonary mycosis
 CF-Cystic fibrosis
 TLR-Toll-like receptor

specific IgE antibodies are lacking for many of these fungi involved in ABPM, investigators need to prepare their own reagents or refer patients and/or samples to specialized centers for evaluation. It is likely that additional case reports of ABPM will appear due to the spectrum of fungi in the environment and the increasing prevalence of asthma.

CRITERIA FOR DIAGNOSIS OF ABPA

In a 2012 review in *The Journal of Allergy and Clinical Immunology*, the criteria for diagnosis were presented as follows: "The minimal criteria required for the diagnosis of ABPA are as follows: (1) asthma or [cystic fibrosis] with deterioration of lung function, (2) immediate *Aspergillus* species skin test reactivity, (3) total serum IgE level of 1000 ng/mL (416 IU/mL) or greater, (4) increased *Aspergillus* species-specific IgE and IgG antibodies, and (5) chest radiographic infiltrates. (See Table 2) Additional criteria might include peripheral blood eosinophilia, *Aspergillus* species serum precipitating antibodies, central bronchiectasis, and *Aspergillus* species-containing mucus plugs."¹⁸

In 2003, the ABPA Consensus Conference of the Cystic Fibrosis Foundation¹⁹ proposed that ABPA be diagnosed for a classic case as follows: (1) acute or subacute clinical deterioration (increased cough, wheezing, exercise induced asthma, increased sputum, decrease in pulmonary function), (2) serum total IgE concentration >1000 kU/L unless the patient is receiving systemic corticosteroids, (3) immediate cutaneous reactivity (skin prick test) to *Aspergillus* or the presence of serum IgE-*A fumigatus*, and (4) precipitating antibodies to *A fumigatus* or serum IgG-*A fumigatus*. The minimal diagnostic criteria are (1) acute or subacute clinical deterioration (increased cough, wheezing, exercise induced asthma, increased sputum, decrease in pulmonary function); (2) serum total IgE concentration >500 kU/L (If ABPA is suspected and the total serum IgE level is 200 to 500 kU/L, repeat the total serum IgE in 1 to 3 months. If the patient is using oral corticosteroids, repeat the total serum IgE when steroid treatment has been discontinued¹⁹); (3) immediate cutaneous reactivity (skin prick test) or the presence of serum IgE-*A fumigatus*; (4) one of the following: (a) precipitates to *A fumigatus* or demonstration of IgG-*A fumigatus* or (b) new or recent abnormalities on chest radiography (infiltrates or mucus plugging) or computed tomography of the chest (bronchiectasis) that has not cleared with antibiotics and standard physiotherapy.¹⁹ Potential diagnostic tools related to detection of fungal infection or colonization include findings from studies of invasive aspergillosis²⁰ and cystic fibrosis (CF),²¹ which consist of enzyme assays for detection of antigenic side chains of *Aspergillus* galactomannan,²⁰ 1,3-β-D-glucan, which is the cell wall component of *A fumigatus* and other fungi,²⁰ and *A fumigatus* DNA by PCR.²⁰ The latter methodology detects viable and dead fungal organisms and inert spores.²¹

GENETIC RISK FACTORS

Genetic studies may provide potential aids in diagnosis and pathogenesis. For example, HLA-DR restriction has been shown

TABLE I. Fungi associated with ABPM

Organism	Study
<i>Aspergillus fumigatus</i>	Hinson et al, 1952 ³
<i>Aspergillus ochraceus</i>	Greenberger, 1988 ⁴
<i>Aspergillus oryzae</i>	Akiyama et al, 1987 ⁵
<i>Aspergillus terreus</i>	Elliott and Newman-Taylor, 1997 ⁶
<i>Alternaria alternata</i>	Chowdhary et al, 2012 ⁷
<i>Bipolaris (Dreschleria) hawaiiensis</i>	McAleer et al, 1981 ⁸
<i>Candida albicans</i>	Akiyama et al, 1984 ⁹
<i>Cryptococcus neoformans</i>	Arora and Huffnagle, 2005 ¹⁰
<i>Curvularia lunata</i>	Halwig et al, 1985 ¹¹
<i>Fusarium vasinfectum</i>	Backman et al, 1995 ¹²
<i>Geotrichum candidum</i>	Elliott and Newman-Taylor, 1997 ⁶
<i>Helminthosporium</i> species	Hendrich et al 1982 ¹³
<i>Penicillium</i> species	Elliott and Newman-Taylor, 1997 ⁶
<i>Pseudoallescheria boydii</i>	Elliott and Newman-Taylor, 1997 ⁶
<i>Sacchromyces cerevisiae</i>	Ogawa et al, 2004 ¹⁴
<i>Schizophyllum commune</i>	Kamei et al, 1994 ¹⁵
<i>Stemphyllium lanuginosum</i>	Benatar et al, 1980 ¹⁶
<i>Torulopsis glabrata</i> (now designated <i>Candida glabrata</i>)	Patterson et al, 1982 ¹⁷

TABLE II. Diagnostic criteria for ABPA in patients with asthma or CF

Patients with asthma or CF (2012 Criteria in Ref 18)
Asthma or, if CF, with deterioration of lung function
Immediate skin reactivity to <i>Aspergillus</i> species
Total serum IgE ≥ 1000 ng/mL (416 IU/mL)*
Increased <i>Aspergillus</i> species-specific IgE and IgG antibodies
Chest roentgenographic infiltrates
"Additional criteria might include peripheral blood eosinophilia, <i>Aspergillus</i> species serum precipitating antibodies, central bronchiectasis, and <i>Aspergillus</i> species-containing mucus plugs" ¹⁸
ABPA Consensus Conference of the Cystic Fibrosis Foundation (Ref 19)
Acute or subacute clinical deterioration (increased cough, wheezing, exercise-induced asthma, increased sputum, decrease in pulmonary function)
Total serum IgE concentration >1000 kU/L unless the patient is receiving systemic corticosteroids
Immediate cutaneous reactivity (skin prick test) to <i>Aspergillus</i> or presence of serum IgE- <i>A fumigatus</i>
Precipitating antibodies to <i>A fumigatus</i> or serum IgG- <i>A fumigatus</i>
If the total serum IgE concentration is >500 but ≤1000 kU/L, then repeat it, especially if the patient no longer requires oral corticosteroids. See text for criteria when the total IgE is 200-500 kU/L

*1 IU/mL = 1 kU/L = 2.4 ng/mL.

to be a risk factor for the development of ABPA. Chauhan et al²²⁻²⁴ observed that patients with asthma and patients with CF who expressed HLA-DR2 and/or HLA-DR5 but lacked HLA-DQ2 were at increased risk for ABPA after exposure to *A fumigatus*. In particular, HLA-DR2, HLA-DRB1*1501, and HLA-DRB1*1503 genotypes were reported to provide high relative risk. Further studies indicated that the presence of HLA-DQ2, especially DQB1*0201, provided protection from the development of ABPA. Brouard et al²⁵ reported that the -1082GG genotype of the IL-10 promoter was associated with colonization of *A fumigatus* and the development of ABPA in CF. The -1082GG

TABLE III. Patients and practice settings of 508 allergist/immunologists who completed a survey about their patients with ABPA

Patients	Results, no. (%)
Patients with ABPA in the past year	
No	263 (51.8)
Yes	245 (48.2)
1-5 patients	214 (87.3)
6-10 patients	23 (9.4)
>11 patients	8 (3.3)
Patients with CF and with ABPA	40 (16.3)
1-5 patients	36 (14.7)
6-10 patients	3 (1.2)
>11 patients	1 (0.4)
Practice setting of physicians with patients with ABPA	
Rural area	9 (3.7)
Metropolitan area population	
<100,000	33 (13.5)
100-999,000	84 (34.3)
>1,000,000	116 (47.3)
Missing	3 (1.2)

TABLE IV. Diagnostic criteria used by 245 allergist/immunologists who diagnosed ABPA in the past year

Study	No. (%) of allergist/immunologists treated previously
Patients with asthma and with ABPA	205 (83.7)
Patients with CF and with ABPA	40 (16.3)
<i>A fumigatus</i> SPT	188 (76.7)
<i>A fumigatus</i> IDST	104 (42.4)
Anti- <i>A fumigatus</i> IgE	157 (64.1)
PST and/or IDST, anti <i>A fumigatus</i> IgE	231 (94.3)
<i>A fumigatus</i> precipitins	127 (51.8)
Anti- <i>A fumigatus</i> IgG	99 (40.4)
Af precipitins antibodies/anti- <i>A fumigatus</i> IgG	175 (71.4)
Total IgE \geq 417 IU/mL	110 (44.9)
Total IgE \geq 1000 IU/mL	103 (42.0)
Peripheral blood eosinophils \geq 400/ μ L	54 (22.0)
Bronchiectasis	122 (49.8)

IDST, Intradermal skin test; SPT, skin prick test.

polymorphism has been associated with increased IL-10 synthesis; whereas, the *-1082A* allele has lower IL-10 synthesis. Saxena et al²⁶ reported that patients with ABPA and with polymorphisms (ala91pro, arg94arg) in the collagen region of pulmonary surfactant protein A2 had elevated total IgE concentrations and higher percentages of eosinophilia than observed in those patients who lacked the single nucleotide polymorphisms. They also found that 80% of patients carrying both alleles had ABPA (odds ratio 10.4; $P = .0079$), whereas only 50% and 60% of patients carrying each allele, individually, were subjects with ABPA, which suggests an additive effect.²⁶ It is theorized that changes in conformation or affinity of surfactant protein A2 may decrease these interactions and compromise host defense.

Miller et al²⁷ examined mutations in the CF transmembrane conductance regulator gene in subjects with asthma who did not

TABLE V. Medications and/or testing by 245 allergist/immunologists for patients with ABPA in the past year

Treatment or test	Patients, no. (%)
OCS	238 (97.1)
OCS + ICS	124 (50.6)
OCS, no ICS	26 (10.6)
Antifungal alone	3 (1.2)
OCS-ICS + antifungal	101 (41.2)
Voriconazole and/or posaconazole	65 (26.5)
Omalizumab	23 (9.4)
ACTH stimulation test	
1 mo	13 (5.3)
3-6 mo	36 (14.7)

ICS, Inhaled corticosteroid; OCS, oral corticosteroid.

have a diagnosis of CF. Mutations were present at a higher frequency in patients with asthma who developed ABPA, 6 of 21 (28.5%), versus control patients with asthma, 2 of 43 (4.6%). These patients with ABPA were heterozygous for the mutations. It is unclear what effect heterozygous cystic fibrosis transmembrane conductance regulator mutations may have on mucus quality in airways of patients with asthma. Carvalho et al²⁸ examined Toll-like receptor (*TLR*) polymorphisms of *TLR2*, *TLR4*, and *TLR9* in cavitary pulmonary aspergillosis, severe asthma associated with fungal sensitization, and patients with ABPA. Patients with ABPA had increased frequency of allele C for the *TLR9* T-1237C polymorphism compared with control patients. TLR-9 is a receptor that recognizes CpG motifs prevalent in bacterial and viral DNA. Novak et al²⁹ reported that the *TLR9* C allele of T-1237C decreases expression. Thus, decreased TLR-9 protective function may be an underlying susceptibility in the development of ABPA.

DIAGNOSTIC CRITERIA BY ALLERGIST/IMMUNOLOGISTS

The results from a survey carried out by the AAAAI in 2012 are presented in Tables III to V. By using the AAAAI's database of 5155 US physicians, members and fellows were contacted on multiple occasions. (see Appendix E1 in this article's Online Repository at www.jaci-inpractice.org for the questionnaire). The response rate was 9.8% (508 physicians). Of these, 245 allergist/immunologists answered affirmatively to question 1 (Appendix E1) that they had seen a patient with ABPA in the past year and provided demographic information about their practice locations and range of patients with ABPA seen in the past year (Table III). The range of diagnostic criteria used are presented in Table IV. There is an evenly divided difference between using the total IgE concentration of \geq 417 IU/mL (kU/L) by 44.9% respondents and \geq 1000 IU/mL (kU/L) by 42% respondents. In retrospect, some results may be attributable to the order of questions in the survey (Appendix E1, question 3 comes after both 1 and 2 and should have come after 1 to focus on ABPA and the same question coming after question 2 to focus on CF). Alternatively, because 83.7% of respondents referred to patients with ABPA, it is suspected that some of the difference in concentration of total IgE as a criterion does apply to ABPA. Bronchiectasis was a diagnostic criteria by 49.8% of the respondents. These data emphasize the need to clarify diagnostic criteria to increase (enhance) uniform application.

TABLE VI. Stages of ABPA of patients with asthma

Stage	Radiography on chest roentgenogram or computed tomography of lungs (examples)	Total IgE concentration
I (acute)	Homogeneous infiltrates, mucus plugging, consolidation or lobar collapse, "tree-in-bud" findings, bronchiectasis	Elevated
II (remission)	No infiltrates	Normal or elevated but less than in stage I
III (exacerbation)	As in stage I	Elevated (double that of stage 2)
IV (steroid-dependent asthma)	No infiltrates, can have atelectasis or hyperinflation from asthma (if an exacerbation occurs, then pulmonary infiltrates such as in stage I can be present)	Elevated or normal
V (end-stage fibrotic)	Scarring, hyperinflation, chronic infiltrates, fibrosis or cavities or fibrocavitary findings	Normal or elevated

MANAGEMENT OF ABPA

Treatment goals

The overall goals are 4-fold: (1) control of symptoms of asthma or CF, (2) prevent or treat pulmonary exacerbations of ABPA, (3) reduce or remit pulmonary inflammation, and (4) mitigate progression to end-stage fibrotic or cavitary disease (Table VI). Early and aggressive treatment of ABPA has the greatest likelihood of preventing progression to end-stage fibrotic lung disease (stage V).³⁰⁻³⁴ After therapy, many patients with stage I (acute stage) and stage III (exacerbation stage) can enter complete remission, stage II, represented by a 35% to 50% reduction in total serum IgE by 6 weeks, clearing of pulmonary infiltrates and symptomatic improvement. Unfortunately this may not be permanent because some patients relapse and have additional pulmonary infiltrates.^{33,34} Earlier diagnosis and treatment appears to lower the risk of advancement to stage IV (glucocorticosteroid dependent) or stage V (fibrocavitary disease).³⁴

Exposure

Bioaerosols of very large numbers of fungi (with bacteria and endotoxins) occur from disturbing organic waste and have been associated with ABPA in 2 of 28 garden waste collectors.³⁵ We were unable to find evidence to make a strong recommendation to minimize exposure to fungi through avoidance and mitigation, such as from moldy basements, water damaged buildings, saunas, and indoor areas with improper home ventilation. Although these are prime locations for growth of molds,³⁶ and can be pertinent for patients with asthma and allergic rhinitis, there is a lack of evidence to make a strong recommendation regarding prevention of pulmonary infiltrates in ABPA.

Therapeutics

Oral corticosteroids. Corticosteroids remain the mainstay in the management of ABPA, by targeting the inflammatory response triggered by *A fumigatus*.³⁴ Most patients with ABPA require periods of oral steroid treatment, followed by tapering doses. Dosing of oral steroids for ABPA has not been well defined. Lower dose oral steroids have been associated with a higher rate of relapse, whereas higher doses for longer duration have a higher remission rate. A common strategy is 2 weeks of daily prednisone 0.5 mg/kg, followed by 6 to 8 weeks of alternate day therapy and then tapering by 5 to 10 mg every 2 weeks.³⁴ A more aggressive approach^{32,33} is prednisolone 0.75 mg/kg/d for 6 weeks, then 0.5 mg/kg/d for 6 weeks, followed by a tapering dose

of 5 mg every 6 weeks to continue for a total duration of 6 to 12 months.

Oral steroids are important in the control of symptoms and reducing the likelihood of relapse. Patients are considered in remission when they remain without pulmonary infiltrates and/or eosinophilia for 6 months after oral steroid withdrawal.³⁴ A useful marker of disease activity and success of therapy is a total serum IgE concentration. Total serum IgE is monitored every 6 to 8 weeks after the initiation of oral steroids and is continued for 1 year thereafter. The goal is to achieve a 35% to 50% reduction of total serum IgE, which leads to clinical and radiologic improvement. Chest imaging, either by chest radiograph or high-resolution chest computed tomography, after 4 to 8 weeks of initiation of oral steroid therapy, is important to assess resolution of infiltration. Spirometry also is a useful tool to objectively assess response to therapy.⁴⁰

Intravenous corticosteroids. Pulse therapy with monthly intravenous methylprednisolone at a dose of 10 to 20 mg/kg/d for 3 consecutive days, in conjunction with itraconazole, has been demonstrated effective in both reduction in subjective symptoms as well as objective measurements.^{37,38} This may be a consideration of patients who demonstrated resistance to oral therapy. A potent inhibitor of CYP3A4, itraconazole increases concentrations of methylprednisolone but not prednisolone and can cause suppression of cortisol secretion.³⁹

Inhaled corticosteroids. Inhaled corticosteroids are a central component in the management of persistent asthma; however, in the dosage equivalent of 400 to 800 µg of beclomethasone dipropionate, when combined with a long-acting β-agonist, they have not been shown to be effective in preventing increasing concentrations of total IgE.⁴⁰ Although symptoms of asthma were improved, they could not be controlled completely.⁴⁰ The researchers concluded that "High doses of [inhaled corticosteroids] alone have no role in the management of ABPA-S and should not be used as first-line therapy."³⁹

Antifungals. Antifungals play an important, yet adjunctive role in the management of ABPA. Antifungals may reduce the requirement for prolonged high-dose systemic corticosteroids by decreasing the burden of fungal colonization and attenuating inflammatory responses. The majority of the literature that addressed antifungal therapy focus on the use of amphotericin and the azoles (ketoconazole, itraconazole, voriconazole, and posaconazole). In recent years, the use of amphotericin B and

ketoconazole has been replaced by antifungals with fewer potential adverse effects.

Itraconazole. Among the antifungals used to treat ABPA, itraconazole is the most commonly recommended. Itraconazole has been demonstrated to significantly reduce total serum IgE, sputum eosinophils, and, most importantly, decrease symptoms and the oral steroid requirement.^{41,42} Itraconazole is recommended for those patients who are steroid dependent and for those who have relapse after a course of steroids. The recommended adult dose for itraconazole is 200 mg twice daily for 4 to 6 months and then tapered over the next 4 to 6 months. As mentioned earlier, it is important to note that itraconazole can inhibit the metabolism of methylprednisolone. Renal function and concurrent medication usage also should be monitored. As with most azoles, adverse drug reactions are not uncommon and include nausea and vomiting, diarrhea, flatulence, hyperlipidemia, hypokalemia, and elevated liver enzymes. Phototoxicity and photosensitivity (UVA) have been reported.⁴³ An alternative approach is for courses of 4 to 6 months.⁴⁴⁻⁴⁵ As with any antimicrobial agent, resistance to azoles is well known, and fungal sensitivities may need to be obtained with some patients (University of Texas Health Sciences Center at San Antonio, Department of Pathology, 7703 Floyd Curl Drive, MC 7750, Room 329E, San Antonio, TX 78229-3900. Ph: 210 567 4131, Fax: 210 567 4076).

Other azoles. Voriconazole and posaconazole are reported to be an effective adjunct therapy in the management of ABPA, with clinical improvement in 70% of patients with ABPA treated with voriconazole and 78% of patients with ABPA treated with posaconazole.^{46,47} Adverse effect profiles were similar to itraconazole in 40% of those treated with voriconazole and 22% of those treated with posaconazole.⁴⁶ Dosing of voriconazole in adult patients is 300 to 600 mg/d and posaconazole 880 mg/d, adjusted by plasma monitoring. The target predose voriconazole plasma level was 1.3 to 5.7 mg/mL. The target posaconazole random plasma level was >0.7 mg/L. For patients who did not improve when on itraconazole, at least 70%, who tolerated either voriconazole or posaconazole, responded favorably.⁴⁷

mAb therapy. There have been a few case reports that demonstrated benefit of omalizumab in the management of ABPA, in which some patients had concurrent CF.⁴⁸⁻⁵⁰ A trial of omalizumab with 16 patients with asthma and ABPA demonstrated significant reductions in exacerbations and steroid requirement, although it did not demonstrate improvement in spirometry.⁵¹ Reduction in exacerbations of asthma and oral steroid requirements has been reported.⁵² This potential adjunct in ABPA management, with a low adverse effect profile, warrants double-blinded, randomized, controlled trials. The role of treatment with antibodies to IL-4R α (dupilumab), IL-5 (mepolizumab), IL-13 (lebrizumab), or other targets in ABPA remains speculative.

Treatments and tests by allergist/immunologists

The AAAAI survey results regarding treatment and testing approaches are presented in Table V. Oral corticosteroids with or without inhaled corticosteroids were administered by 97% of the respondents. Antifungals plus corticosteroids were used by 41% of respondents. The distribution of medications or their combinations could reflect varying stages of ABPA (pulmonary infiltrates or none), repetitive expectoration of sputum plugs or none, ease or

difficulty of treatment of concomitant asthma or ABPA, and physician and patient preferences among other explanations.

SUMMARY

As the worldwide prevalence of asthma has increased, it appears that the prevalence of ABPA also has increased. Thus, ABPA is no longer a rare condition and has been recognized as a specific subtype (endotype) of asthma.⁵³ The results of the study of allergist/immunologists in the AAAAI suggest that uniform criteria for diagnosis are needed, especially as to the cutoff of total IgE concentration (and the appropriate units, eg, kU/L or IU/mL, in which it is expressed), and that controlled trials would be informative to understand the place in therapy of all of the therapies that are used. Establishing separate registries of patients with ABPA with asthma and with CF in terms of risk factors, exposures, and diagnostic criteria and treatment, would provide valuable information in better understanding and treating ABPA.

REFERENCES

- Denning DW, Pleuvy A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. *Med Mycol* 2013;51:361-70.
- Greenberger PA. When to suspect and work up allergic bronchopulmonary aspergillosis. *Ann Allergy Asthma Immunol* 2013;111:1-4.
- Hinson KFW, Moon AJ, Plummer NS. Bronchopulmonary aspergillosis: a review and report of eight new cases. *Thorax* 1952;7:317-33.
- Greenberger PA. Allergic bronchopulmonary aspergillosis and fungoses. *Clin Chest Med* 1988;9:599-608.
- Akiyama K, Takizawa H, Suzuki M, Miyachi S, Ichinohe M, Yanagihara Y. Allergic bronchopulmonary aspergillosis due to *Aspergillus oryzae*. *Chest* 1987;91:2856.
- Elliott MW, Newman-Taylor AJ. Allergic bronchopulmonary aspergillosis. *Clin Exp Allergy* 1997;27(Suppl1):55-9.
- Chowdhary A, Agarwal K, Randhawa HS, Kathuria S, Gaur SN, Najafzadeh MJ, et al. A rare case of allergic bronchopulmonary mycosis caused by *Alternaria alternata*. *Med Mycol* 2012;50:890-6.
- McAleer R, Kroenert DB, Elder JL, Froudast JH. Allergic bronchopulmonary disease caused by *Curvularia lunata* and *Drechslera hawaiiensis*. *Thorax* 1981;36:338-44.
- Akiyama K, Mathison DA, Riker JB, Greenberger PA, Patterson R. Allergic bronchopulmonary candidiasis. *Chest* 1984;85:699-701.
- Arora A, Huffnagle GB. Immune regulation during allergic bronchopulmonary mycosis: lessons taught by two fungi. *Immunol Res* 2005;33:53-68.
- Halwig JM, Brueske DA, Greenberger PA, Dreisin RB, Sommers HM. Allergic bronchopulmonary curvulariosis. *Am Rev Respir Dis* 1985;132:186-8.
- Backman KS, Roberts M, Patterson R. Allergic bronchopulmonary mycosis caused by *Fusarium vasinfectum*. *Am J Respir Crit Care Med* 1995;152:1379-81.
- Hendrich DJ, Ellithrope DB, Lyon F, Hattier P, Salvaggio JE. Allergic bronchopulmonary helminthosporiosis. *Am Rev Respir Dis* 1982;126:935-8.
- Ogawa H, Fujimura M, Tofuku Y. Allergic bronchopulmonary fungal disease caused by *Saccharomyces cerevisiae*. *J Asthma* 2004;41:223-8.
- Kamei K, Unno H, Nagao K, Kuriyama T, Nishimura K, Miyaji M. Allergic bronchopulmonary mycosis caused by the basidiomycetous fungus *Schizophyllum commune*. *Clin Infect Dis* 1994;18:305-9.
- Benatar SR, Allan B, Hewitson RP. Allergic bronchopulmonary stempylitis. *Thorax* 1980;35:515-8.
- Patterson R, Samuels BS, Phair JJ, Roberts M. Bronchopulmonary totulopsiosis. *Int Arch Allergy Appl Immunol* 1982;69:30-3.
- Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. *J Allergy Clin Immunol* 2012;129:280-91.
- Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger PA, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. *Clin Infect Dis* 2003;37(Suppl 3):S225-64.
- Mennink-Kersten MASH, Ruegebrink D, Wasei N, Melchers WJG, Verweij PE. In vitro release by *Aspergillus fumigatus* of galactofuranose antigens, 1,3- β -D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. *J Clin Microbiol* 2006;44:1711-8.

21. Baxter CG, Moore CB, Jones AM, Webb AK, Denning DW. IgE-mediated immune responses and airway detection of *Aspergillus* and *Candida* in adult cystic fibrosis. *Chest* 2013;143:1351-7.
22. Chauhan BA, Knutsen AP, Hutcheson PS, Slavin RG, Bellone CJ. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. *J Clin Invest* 1996;97:2324-31.
23. Chauhan B, Santiago L, Kirschmann DA, Hauptfeld V, Knutsen AP, Hutcheson PS, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. *J Immunol* 1997;159:4072-6.
24. Chauhan B, Santiago L, Hutcheson PS, Schwartz HJ, Spitznagel E, Castro M, et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol* 2000;106:723-9.
25. Brouard J, Knauer N, Boelle P-Y, Corvol H, Henrion-Caude A, Flamant C, et al. Influence of interleukin-10 on airways colonization by *Aspergillus fumigatus* in cystic fibrosis patients. *J Infect Dis* 2005;191:1988-91.
26. Saxena S, Madan T, Shah A, Muralidhar K, Sarma PA. Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol* 2003;111:1001-7.
27. Miller PW, Hamosh A, Macej M Jr, Greenberger PA, MacLean J, Walden SM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. *Am J Hum Genet* 1996;59:45-51.
28. Carvalho A, Pasqualotto AC, Pitzurra L, Romani L, Denning DW, Rodrigues F. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. *J Infect Dis* 2008;197:618-21.
29. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J, et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. *Allergy* 2007;62:766-72.
30. Mahdavinia M, Grammer LC. Management of allergic bronchopulmonary aspergillosis: a review and update. *Ther Adv Respir Dis* 2012;6:173-87.
31. Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. *Clin Chest Med* 2012;33:265-81.
32. Agawal R. Allergic bronchopulmonary aspergillosis. *Chest* 2009;135:805-26.
33. Agarwal R, Gupta D, Agarwal AN, et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending chest clinic in north India. *Chest* 2006;130:442-8.
34. Greenberger PA. Allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol* 2002;110:685-92.
35. Poole CJM, Wong M. Allergic bronchopulmonary aspergillosis in garden waste (compost) collectors: occupational implications. *Occup Med* 2013;63:517-9.
36. Centers for Disease Control. Molds in the environment. Available from: www.cdc.gov/mold/faq.htm. Accessed October 7, 2012.
37. Thompson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. *Pediatr Pulmonol* 2006;41:164-70.
38. Cohen-Cymbesknah M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. *J Cyst Fibros* 2009;8:253-7.
39. Lebrun-Vignes B, Corbrion Archer V, Diquet B, Levron JC, Chosidow O, Puech AJ, et al. Effect of itraconazole on the pharmacokinetics of prednisone and methylprednisolone and cortisol secretion in healthy subjects. *Br J Clin Pharmacol* 2001;51:443-50.
40. Agarwal R, Khan A, Aggarwal AN, Saikia B, Gupta D, Chakrabarti A. Role of inhaled corticosteroids in the management of serological allergic bronchopulmonary aspergillosis (ABPA). *Intern Med* 2011;50:855-60.
41. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Antiinflammatory effect of itraconazole on stable allergic bronchopulmonary aspergillosis; a randomized control trial. *J Allergy Clin Immunol* 2003;111:952-7.
42. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. *Cochrane Database Syst Rev* 2004;3:CD001108.
43. Haylett AK, Felton S, Denning DW, Rhodes LE. Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. *Br J Dermatol* 2012;168:179-85.
44. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of a new diagnostic and classification criteria. *Clin Exp Allergy* 2013;43:850-73.
45. Hogan C, Denning DW. Allergic bronchopulmonary aspergillosis and related allergy syndromes. *Semin Resp Crit Care Med* 2011;32:682-92.
46. Moreira AS, Silva D, Reis Ferraira A, Delgado L. Antifungal treatment in allergic bronchiopulmonary aspergillosis with and without cystic fibrosis: a systematic review. *Clin Exper Allergy* 2014;44:1210-27.
47. Chrishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. *J Asthma* 2012;49:423-33.
48. Lebecque P, Leonard A, Pileete C. Omalizumab for treatment of allergic bronchopulmonary aspergillosis exacerbations in cystic fibrosis patients. *Pediatr Pulmonol* 2009;44:546.
49. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis with cystic fibrosis with anti-IgE antibody (omalizumab). *Pediatr Pulmonol* 2008;43:1249-51.
50. van der Ent CK, Hoestra H, Rijkers GT, et al. Successful treatment of ABPA with recombinant anti-IgE antibody. *Thorax* 2007;62:267-77.
51. Tille-Lelond I, Germaud P, Leroyer C, Tétu L, Girard F, Devouassoux G, et al. Allergic bronchopulmonary aspergillosis and omalizumab. *Allergy* 2011;66:1254-6.
52. Moss RB. The use of biologic agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. *Ann NY Acad Sci* 2012;1272:49-57.
53. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol* 2011;127:355-60.